Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases... Show more
The 10-day RSI Indicator for XNCR moved out of overbought territory on October 21, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where XNCR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on November 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XNCR as a result. In of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for XNCR turned negative on October 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
XNCR broke above its upper Bollinger Band on October 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The 50-day moving average for XNCR moved above the 200-day moving average on October 31, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 132 cases where XNCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.643) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (7.082) is also within normal values, averaging (322.723).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a developer of therapeutics to treat autoimmune and allergic diseases, cancer and other conditions
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| ICFSX | 10.12 | 0.04 | +0.40% |
| ICON Consumer Select Institutional | |||
| PASSX | 59.07 | 0.10 | +0.17% |
| T. Rowe Price Small-Cap Stock Adv | |||
| RWCEX | 14.47 | 0.02 | +0.14% |
| Redwheel Global Emerging Equity Ins | |||
| TEMUX | 17.89 | N/A | N/A |
| Morgan Stanley Pathway Em Mkts Eq | |||
| FMSTX | 35.53 | N/A | N/A |
| Federated Hermes MDT Large Cap Value IS | |||
A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with NUVL. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then NUVL could also see price increases.
| Ticker / NAME | Correlation To XNCR | 1D Price Change % | ||
|---|---|---|---|---|
| XNCR | 100% | -3.23% | ||
| NUVL - XNCR | 61% Loosely correlated | +0.91% | ||
| CRNX - XNCR | 59% Loosely correlated | -0.28% | ||
| NRIX - XNCR | 55% Loosely correlated | -5.37% | ||
| IDYA - XNCR | 55% Loosely correlated | -0.19% | ||
| RCUS - XNCR | 54% Loosely correlated | -1.43% | ||
More | ||||